Inhaled glucocorticoids in treatment of covid-19

Czech version

Authors: Milan Sova ^1,2; Ondřej Zela ³
Authors‘ workplace: Klinika nemocí plicních a tuberkulózy, Fakultní nemocnice Brno ¹; Klinika plicních nemocí a tuberkulózy, Fakultní nemocnice Olomouc ²; Interní oddělení Nemocnice ve Frýdku-Místku ³
Published in: Vnitř Lék 2021; 67(6): 328-329
Category: Main Topic

Overview

Covid-19 pandemic affects heavily different health care systems. The most important factor/aspect is high number of hospitalized patients in countries with low level of infrastructure. Because of this, many therapeutic methods reducing the risk of more severe course of disease are now under development. The key part of this review is the STOIC trial, which is the largest, randomized trial assessing the effect of inhaled glucocorticoid treatment on the risk of hospitalization due to covid-19.

Keywords:

glucocorticoids – COVID-19

Sources

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506.

2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18): 1708–20.

3. Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018; 197(6): 757–67.

4. Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. Bmj. 2020;370:m2980.

5. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report. medRxiv. 2020:2020.06.22.20137273.

6. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020; 324(13): 1307–16.

7. Kalyanaraman Marcello R, Dolle J, Grami S, Adule R, Li Z, Tatem K, et al. Characteristics and outcomes of COVID-19 patients in New York City's public hospital system. PLoS One. 2020; 15(12): e0243027.

8. Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et al. The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells. J Virol. 2020; 95(1).

9. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al. COVID- -19-related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids. Am J Respir Crit Care Med. 2020; 202(1): 83–90.

10. Ramakrishnan S, Nicolau DV, Jr., Langford B, Mahdi M, Jeffers H, Mwasuku C, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021; 9(7): 763–72.